Orphan Drugs Show Potential With 600 Drugs in Pipeline

Release Date: 22-Sep-2014

Global Orphan Drug Market Report Findings:

• Orphan Designated Drugs in Clinical Phase: 600
• Marketed Orphan Designated Drugs: 281
• Highest Number of Drugs in Phase-2 Trial: 231
• US Dominates Clinical Trial Process: 350 in Pipeline (Research till Registration)
• Indication for Clinical Trials for Orphan Drug: More than 30% for Cancer Treatment
• Share of Biological in Orphan Drug: More than 60%
• Major Market: US (Sales > US$ 40 Billion)

Key Highlights of Report

• Why Shift to Orphan Drugs
• Global & Regional Orphan Drug Market Overview
• Orphan Drug Designation Criteria Across US, Europe & Asia
• Market Specific Reimbursement Policy for US, Europe & Asia
• Regulatory Framework for US, Europe & Asia
• Orphan Drug Pipeline by Phase, Orphan Designated Indication & Country
• Competitive Landscape

The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.

With the marketing exclusivity in rule, the manufacturing company has an incentive to fix the price of the orphan drug at significant high levels. The payers of health care do not have significant negotiation power and are constantly under pressure from patient advocacy groups and media to accommodate new drugs. Also, these payers seldom do not have adequate and complete information about the cost structure of orphan drugs. Thus, they are, in most cases, forced to accept the price fixed by the manufacturers.

For Report Sample Visit: Global Orphan Drug Market Outlook 2018

Or Contact: neeraj@kuickresearch.com +91-11-47067990